期刊文献+

扎来普隆含量测定方法的研究 被引量:1

Study on assay of zaleplon
下载PDF
导出
摘要 目的 建立测定原料及胶囊中扎来普隆含量的方法。方法 用高效液相色谱法 ,色谱柱为WatersSpherisorbS5ODS2 (5μm ,4 6mm× 2 5 0mm)分析柱 ,流动相为甲醇 0 0 1mol·L-1磷酸溶液 (5 7∶4 3) ,流速 1 0mL·min-1,柱温为 2 5℃ ,检测波长为 2 31nm。结果 方法的精密度和稳定性均良好 ;扎来普隆浓度在 0 0 113~ 0 0 6 75mg·mL-1内 ,峰面积与浓度呈良好的线性关系 (r=0 9998) ,平均回收率为 99 7% ;扎来普隆与其相邻杂质峰的分离度符合要求。结论 方法简便、专属、重现性好 ,可用于扎来普隆原料及其它制剂的含量测定。 OBJECTIVE: To develop a method for the determination of zaleplon in its pharmaceutical material and preparation. METHODS: A RP-HPLC method was used with Waters Spherisorb S5 ODS2 (5 μm, 4.6 mm × 250 mm) column. The mobile phase was a mixture of methanol -0.01 mol&middotL-1 phosphoric acid (57:43) and the flow rate was 1.0 mL&middotmin-1, and column temperature 25°C, with the detection wavelength at 231 nm. RESULTS: The precision and stability were fine. The linear correlation was observed from the concentrations of 0.011 3 mg&middotmL-1 to 0.067 5 mg&middotmL -1 (r = 0.999 8). The average recovery was 99.7%. Resolution between zaleplon peak and other peaks met the requirements. CONCLUSION: The method was convenient, selective and reproducible.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2004年第3期220-221,共2页 Chinese Pharmaceutical Journal
关键词 扎来普隆 含量测定 高效液相色谱法 镇静催眠药 抗惊厥药 Correlation methods High performance liquid chromatography Mixtures Stability Synthesis (chemical)
  • 相关文献

参考文献1

二级参考文献9

  • 1[1]Beer. A review of the preclinical development of zaleplon, a novel non-benzodiazepine hypnotic for the treatment of insomnia. CNS Drug Reviews, 1997; 3: 210~215.
  • 2[2]Sanger DJ ,Morel E,Perrault G.Comparison of the pharmacological profiles of the hypnotic drugs,zaleppon and zolpidem .Eur J Pharmacol, 1996; 313(1~2):35~42.
  • 3[3]Jacques G, France V. Pharmacokinetics and anticonvulsant effect of a new hypnotic ,CL 284,846,in rats. Pharmaceutical Research, 1995; 12: 1592~1597.
  • 4[4]Amy S R, Mona D,et al. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos, 1999; 20:171~175.
  • 5[5]David J G, Jerold S H,et al.Comparative kinetics and dynamics of zaleplon, zolpidem,and placebo.Clinical Pharmacology & Therzpeutics, 1998; 553~560.
  • 6[6]Kimberly E. Vanover, et al,Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic. Psychopharmacology, 1994; 115: 289~296.
  • 7[7]Ator NA, Griffiths RR. Differential generalization to pentobarbital in rats trained to discriminate lorazepam chlordiazepoxide diazepam or triazolam. Psychopharmacology, 1989; 98:20~30.
  • 8[8]Craig R.R. Zaleplon and triazolam in humans:acute behavioral effects and abuse potemtial. Psychopharmacology, 1999; 145: 39~51.
  • 9[9]Walsh J K, Fry J, Evwin CW, et al. Efficacy and tolerability of 14-day administration of zaleplon 5mg and 10mg for the treatment of primary insomnia. Clin.Drug Invest, 1998; 16: 347~354.

共引文献7

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部